Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin

Alpesh Amin, Jeffrey Trocio, Lin Xie et al.|MEF University Institutional Repository (MEF University)|2015

Cited by 2